On May 5, 2026 Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported its participation in the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 29th Annual Meeting to be held in Boston, MA from May 11-15, 2026. Factor will deliver seven presentations covering the latest preclinical data from Factor’s engineered cell therapy programs, as well as recent advances in Factor’s cell engineering platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to report the last data from our pipeline programs as well as several new innovations at ASGCT (Free ASGCT Whitepaper) 2026," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "From next-generation CAR-T approaches to RNA-enabled cell engineering and off-the-shelf cell therapies, the seven presentations we will present reflect the strength and versatility of the platforms that we have developed at Factor over the past 15 years."

Dr. Kyle Garland, Vice President of Research & Development at Factor, commented, "Over the past year, we have made significant progress developing next-generation therapeutics that have the potential to treat some of the most intractable diseases by overcoming the limitations of conventional therapies. We look forward to engaging with the scientific community in Boston at the ASGCT (Free ASGCT Whitepaper) Annual Meeting and sharing how our recent advancements are moving us closer to transformative patient care."

Details of the presentations are below:

"In vivo CAR-T platform incorporating high-fidelity synthetic RNA enables selective protein expression in CD8+ T cells (1095)" -to be presented by Joseph Pisano on Tuesday, May 12 from 5:00-6:30 pm, in the "Topic C: Gene Addition: Non-Viral Vectors" Poster Session.
"TCR-replaced CAR T cells with a mutant CD28 co-stimulatory domain containing TRAF-binding motifs demonstrate enhanced memory phenotype and reduced exhaustion following tumor rechallenge assays (1260)" -to be presented by Ian Hay on Tuesday, May 12 from 5:00-6:30 pm, in the "Topic F: Pre-Clinical Models for Gene and Cell Therapies of Cancer and Autoimmune Disease" Poster Session.
"Transplant-ready IL-12-engineered iPSC-derived macrophages with solid-tumor killing activity cryopreserved under optimized xeno-free conditions maintain viability post thaw (2179)" -to be presented by Lindsey Sabo on Wednesday, May 13 from 5:00-6:30 pm, in the "Topic G: CMC and Regulatory" Poster Session.
"Engineered iPSC-derived mesenchymal stromal cells improve muscle function and pathology in the mdx mouse model of muscular dystrophy (2501)" -to be presented by Christopher B. Rohde on Wednesday, May 13 from 5:00-6:30 pm, in the "Topic E: Gene-Based Therapies in Pre-Clinical Models of Genetic Disease" Poster Session.
"IL12-secreting macrophages enhance cytotoxic T cell activity against a spheroid glioblastoma multiforme model and overcome the immunosuppressive tumor microenvironment (3289)" -to be presented by Katherine Klosterman on Thursday, May 14 from 5:00-6:30 pm, in the "Topic F: Pre-Clinical Models for Gene and Cell Therapies of Cancer and Autoimmune Disease" Poster Session.
"Efficient RNA-based reprogramming of human fibroblasts without strand slippage-inducing modified nucleotides (3312)" -to be presented by Cassandra Ng on Thursday, May 14 from 5:00-6:30 pm, in the "Topic D: Gene Correction and Modulation" Poster Session.
"Engineered iPSC-derived MSCs expressing serine protease HTRA1 reduce Tau fibrils (3486)" -to be presented by Taeyun Kim on Thursday, May 14 from 5:00-6:30 pm, in the "Topic E: Gene-Based Therapies in Pre-Clinical Models of Genetic Disease" Poster Session.
For more information about the American Society of Genetic & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, visit annualmeeting.asgct.org.

(Press release, Factor Bioscience, MAY 5, 2026, View Source;cell-therapy-asgct-29th-annual-meeting-302763089.html [SID1234665150])

On May 5, 2026 Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company reported the initiation of a global, multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a key milestone in Senhwa’s global clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study will evaluate Senhwa’s first-in-class investigational drug, Pidnarulex (CX-5461), in combination with BeOne Medicines’ marketed PD-1 inhibitor, tislelizumab, across multiple advanced or metastatic solid tumors, including pancreatic cancer, colorectal cancer, and melanoma—areas with significant unmet medical needs. The global multi-center design is expected to accelerate clinical validation while enhancing the asset’s visibility, supporting future out-licensing and commercialization opportunities.

The Company aims to leverage combination therapy approaches to enter the rapidly expanding immuno-oncology market and build sustainable long-term growth momentum.

CX-5461 features a differentiated dual mechanism of action. In addition to inhibiting ribosomal RNA synthesis and suppressing tumor cell proliferation, it stabilizes G-quadruplex structures, inducing DNA damage and activating the cGAS–STING pathway. This unique mechanism not only confers direct anti-tumor activity but also enhances tumor immunogenicity, creating strong synergy with immune checkpoint inhibitors. Preclinical and translational studies have demonstrated that CX-5461 can effectively remodel the tumor microenvironment, increase tumor-infiltrating lymphocytes (TILs), and upregulate PD-L1 expression. These findings suggest its potential to overcome resistance and improve response rates in patients with limited benefit from current immunotherapies, positioning CX-5461 as a promising backbone agent in combination immunotherapy strategies.

According to market research analyses, the global cancer immunotherapy market exceeded US$150 billion in 2025 and is projected to grow at a double-digit compound annual growth rate, potentially surpassing US$300 billion by 2035. Within this expanding landscape, combination therapies have emerged as a central focus for the pharmaceutical industry, serving as a key driver for lifecycle extension and next-generation revenue growth.

At the same time, the pharmaceutical sector is facing increasing pressure from patent expirations of blockbuster drugs, driving strong demand for innovative assets with differentiated mechanisms and clinical potential. Strategic licensing and M&A activities have become primary pathways for large pharmaceutical companies to secure high-value pipeline assets, intensifying competition for early-stage opportunities.

Against this backdrop, the current clinical trial is expected to serve as a critical validation point for CX-5461. Pending positive efficacy and safety outcomes, the asset has the potential to attract strong interest from global pharmaceutical companies for licensing or acquisition, significantly enhancing its commercial prospects and overall market value.

(Press release, Senhwa Biosciences, MAY 5, 2026, View Source [SID1234665149])

On May 5, 2026 AVEO Oncology, an LG Chem company ("AVEO"), reported that two abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 annual meeting this May 29-June 2, 2026, in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC)
First Author: Robert Motzer, MD, Memorial Sloan Kettering Cancer Center
Abstract Number: 4555
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 34
Date and Time: Sunday, May 31, 2026, 9:00am – 12:00 PM CDT

Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC)
First Author: Julie E. Bauman, MD, MPH, George Washington University Cancer Center
Abstract Number: TPS6132
Poster Session: Head and Neck Cancer
Poster Board: 585b
Date and Time: Saturday, May 30, 2026, 1:30 PM – 4:30 PM CDT

(Press release, AVEO, MAY 5, 2026, View Source [SID1234665148])

On May 5, 2026 Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, reported one poster presentation and four poster abstracts in conjunction with it’s pharmaceutical company collaborators at the upcoming 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, May 29-June 2, 2026, McCormick Place, Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Abstract: 2652
Session Title: Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT

Poster Abstracts in Collaboration with BriaCell, a clinical-stage immuno-oncology drug company,

Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.
Abstract: e14535

Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.
Abstract: e15525

Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer.

Abstract Title: Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
Abstract: e14535

Abstract Title: Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
Abstract: e13109

Creatv Bio’s LifeTracDx blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic tools for specific cancer therapies and provided continuous monitoring of cancer patients for pharmaceutical companies to optimize therapy regimes.

(Press release, Creatv Bio, MAY 5, 2026, View Source [SID1234665147])

On May 5, 2026 Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, reported one poster presentation and four poster abstracts in conjunction with it’s pharmaceutical company collaborators at the upcoming 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, May 29-June 2, 2026, McCormick Place, Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Abstract: 2652
Session Title: Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT

Poster Abstracts in Collaboration with BriaCell, a clinical-stage immuno-oncology drug company,

Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.
Abstract: e14535

Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.
Abstract: e15525

Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer.

Abstract Title: Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
Abstract: e14535

Abstract Title: Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
Abstract: e13109

Creatv Bio’s LifeTracDx blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic tools for specific cancer therapies and provided continuous monitoring of cancer patients for pharmaceutical companies to optimize therapy regimes.

(Press release, Creatv Bio, MAY 5, 2026, View Source [SID1234665147])